| タイトル |
Efficacy and safety of omalizumab for the treatment of refractory chronic spontaneous urticaria in Japanese patients: Subgroup analysis of the phase 3 POLARIS study
|
| 著者 |
Hide Michihiro
Igarashi Atsuyuki
Yagami Akiko
Inomata Naoko
Fukunaga Atsushi
Kaiser Guenther
Wang Junyi
Matsushima Soichiro
Greenberg Steven
Khalil Sam
|
| 収録物名 |
ALLERGOLOGY INTERNATIONAL
|
| 巻 | 67 |
| 号 | 2 |
| 開始ページ | 243 |
| 終了ページ | 252 |
| 収録物識別子 |
ISSN 1323-8930
EISSN 1440-1592
|
| 主題 | |
| 言語 |
英語
|
| 資源タイプ | 学術雑誌論文 |
| 出版者 |
JAPANESE SOCIETY ALLERGOLOGY
|
| 発行日 | 2018-04 |
| アクセス権 | メタデータのみ |
| 関連情報 |
[DOI] 10.1016/j.alit.2017.10.001
[PMID] 29102514
|
| 備考 | This subgroup analysis of the POLARIS study was funded by Novartis Pharmaceuticals. The authors acknowledge the assistance of the investigators, clinical trial staff and participants. The authors also thank Aisling O'Keeffe of Novartis Ireland Ltd., Rukaiyya Khan of Novartis Healthcare Private Limited and Asako Itakura of Novartis K.K. for providing medical writing and editorial assistance, and Lydia Michaut for her professional advice on the bioanalysis methods. The authors acknowledge POLARIS Principal Investigators (Japan): Atsushi Fukunaga; Taizo Hamaguchi; Takaaki Hiragun; Atsuyuki Igarashi; Masami Ikeda; Naoko Inomata; Masafumi Ishibashi; Shusaku Ito; Akiko Kakimi; Atsuko Kato; Satomi Kobayashi; Yumiko Kudo; Akihiro Kume; Ichiro Kurokawa; Yoshihiro Kuwano; Kayoko Matsunaga; Eishin Morita; Hideki Mukai; Hiroshi Murata; Hiromitsu Noguchi; Yuko Nomura; Emiko Sawamura; Yoshihiro Sei; Hideyasu Takata; Katsuhiko Tsukamoto; Takahisa Uchida. |
